Similarly, in our study, three of the four surveyed activating receptors (NKG2D, NKp30, and DNAM-1) rebounded in surface expression after successful TKI treatments for CML (Figure S4), and the number of cytotoxic NK cells expressing these activating receptors also reverted or increased simultaneously. This evidence concerns the gene NCR3 and chronic myelogenous leukemia, BCR-ABL1 positive.